WallStreetZenWallStreetZen

NASDAQ: BMRN
Biomarin Pharmaceutical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BMRN

Based on 9 analysts offering 12 month price targets for Biomarin Pharmaceutical Inc.
Min Forecast
$91.00-0.22%
Avg Forecast
$103.44+13.43%
Max Forecast
$117.00+28.29%

Should I buy or sell BMRN stock?

Based on 9 analysts offering ratings for Biomarin Pharmaceutical Inc.
Strong Buy
Strong Buy
5 analysts 55.56%
Buy
2 analysts 22.22%
Hold
2 analysts 22.22%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BMRN stock forecasts and price targets.

BMRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-02-29
lockedlocked$00.00+00.00%2024-02-23
lockedlocked$00.00+00.00%2024-02-23
lockedlocked$00.00+00.00%2024-02-23
lockedlocked$00.00+00.00%2024-01-30
Stifel Nicolaus
Bottom 10%
10
Strong BuyReiterates$101.00+10.75%2023-12-21
BMO Capital
Bottom 4%
4
BuyMaintains$100.00+9.65%2023-11-03
Morgan Stanley
Bottom 10%
10
Strong BuyMaintains$117.00+28.29%2023-11-02
Barclays
Top 33%
68
Strong BuyMaintains$111.00+21.71%2023-11-02

1 of 1

Forecast return on equity

Is BMRN forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is BMRN forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BMRN revenue forecast

What is BMRN's revenue in the next 3 years based on estimates from 12 analysts?
Avg 1 year Forecast
$2.7B+12.86%
Avg 2 year Forecast
$3.1B+26.94%
Avg 3 year Forecast
$3.4B+41.39%
BMRN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BMRN earnings growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?
Company
94.71%
Industry
7.29%
Market
21.81%
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
BMRN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

BMRN revenue growth forecast

How is BMRN forecast to perform vs Biotechnology companies and vs the US market?
Company
12.22%
Industry
37.5%
Market
10.08%
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BMRN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BMRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BMRN$91.20$103.44+13.43%Strong Buy
RPRX$27.98$46.75+67.08%Strong Buy
ALNY$143.80$213.58+48.53%Buy
GMAB$28.47$45.00+58.06%Buy
BGNE$144.12$242.60+68.33%Strong Buy
View Top Biotech Stocks

Biomarin Pharmaceutical Stock Forecast FAQ

Is Biomarin Pharmaceutical Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: BMRN) stock is to Strong Buy BMRN stock.

Out of 9 analysts, 5 (55.56%) are recommending BMRN as a Strong Buy, 2 (22.22%) are recommending BMRN as a Buy, 2 (22.22%) are recommending BMRN as a Hold, 0 (0%) are recommending BMRN as a Sell, and 0 (0%) are recommending BMRN as a Strong Sell.

If you're new to stock investing, here's how to buy Biomarin Pharmaceutical stock.

What is BMRN's revenue growth forecast for 2024-2026?

(NASDAQ: BMRN) Biomarin Pharmaceutical's forecast annual revenue growth rate of 12.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Biomarin Pharmaceutical's revenue in 2024 is $2,419,226,000.On average, 12 Wall Street analysts forecast BMRN's revenue for 2024 to be $515,130,862,263, with the lowest BMRN revenue forecast at $492,632,049,042, and the highest BMRN revenue forecast at $530,555,849,064. On average, 12 Wall Street analysts forecast BMRN's revenue for 2025 to be $579,420,948,406, with the lowest BMRN revenue forecast at $532,744,486,279, and the highest BMRN revenue forecast at $630,742,604,346.

In 2026, BMRN is forecast to generate $645,375,342,210 in revenue, with the lowest revenue forecast at $551,574,313,355 and the highest revenue forecast at $715,835,309,868.

What is BMRN's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BMRN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is BMRN's Price Target?

According to 9 Wall Street analysts that have issued a 1 year BMRN price target, the average BMRN price target is $103.44, with the highest BMRN stock price forecast at $117.00 and the lowest BMRN stock price forecast at $91.00.

On average, Wall Street analysts predict that Biomarin Pharmaceutical's share price could reach $103.44 by Feb 28, 2025. The average Biomarin Pharmaceutical stock price prediction forecasts a potential upside of 13.43% from the current BMRN share price of $91.20.

What is BMRN's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BMRN) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.